title: Long-term results of enterprise stent-assisted coiling of cerebral aneurysms.
abstract: BACKGROUND
  The Enterprise Vascular Reconstruction Device and Delivery System (Cordis; the Enterprise stent) was approved for use in conjunction with coiling of wide-necked aneurysms in 2007. No published long-term aneurysm occlusion or complication data exist for the Enterprise system.
  
  
  OBJECTIVE
  We compiled data on consecutive patients treated with Enterprise stent-assisted coiling of aneurysms from 9 high-volume neurointerventional centers.
  
  
  METHODS
  A 9 center registry was created to evaluate large volume data on the delayed safety and efficacy of the Enterprise stent system. Pooled data were compiled for consecutive patients undergoing Enterprise stent-assisted coiling at each institution prior to May 2009.
  
  
  RESULTS
  Two-hundred twenty-nine patients with 229 aneurysms, 32 of which were ruptured aneurysms, were included in the study. Mean clinical and angiographic follow-up was 619.6 ± 26.4 days and 655.7 ± 25.2 days, respectively. Mean aneurysm size was 9.2 ± 0.4 mm. Fifty-nine percent of patients demonstrated 100% coil obliteration and 81% had 90% or higher occlusion at last follow-up angiography. A total of 19 patients (8.3%) underwent retreatment of their aneurysms during the follow-up period. Angiographic in-stent stenosis was seen in 3.4% and thromboembolic events occurred in 4.4%. Overall, 90% of patients who underwent Enterprise-assisted coiling had a modified Rankin Scale score of 2 or less at last follow-up. A poor modified Rankin Scale score was strongly associated with rupture status (P < .001).
  
  
  CONCLUSIONS
  Although this study is limited by its retrospective nature, the Enterprise stent system appears to be an effective, safe, and durable treatment for intracranial aneurysms when used in conjunction with coiling.
authors.affiliation: Department of Neurosurgery, University of Florida College of Medicine, Gainesville, Florida, USA. Kyle.fargen@neurosurgery.ufl.edu
authors.forename: Kyle M
authors.initials: KM
authors.lastname: Fargen
authors.forename: Brian L
authors.initials: BL
authors.lastname: Hoh
authors.forename: Babu G
authors.initials: BG
authors.lastname: Welch
authors.forename: G Lee
authors.initials: GL
authors.lastname: Pride
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lanzino
authors.forename: Alan S
authors.initials: AS
authors.lastname: Boulos
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Carpenter
authors.forename: Ansaar
authors.initials: A
authors.lastname: Rai
authors.forename: Erol
authors.initials: E
authors.lastname: Veznedaroglu
authors.forename: Andrew
authors.initials: A
authors.lastname: Ringer
authors.forename: Rafael
authors.initials: R
authors.lastname: Rodriguez-Mercado
authors.forename: Peter
authors.initials: P
authors.lastname: Kan
authors.forename: Adnan
authors.initials: A
authors.lastname: Siddiqui
authors.forename: Elad I
authors.initials: EI
authors.lastname: Levy
authors.forename: J
authors.initials: J
authors.lastname: Mocco
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001807:Blood Vessel Prosthesis; D015897:Comorbidity; D005260:Female; D006801:Humans; D002532:Intracranial Aneurysm / Q000401:mortality* / Q000601:surgery*; D008137:Longitudinal Studies; D008875:Middle Aged; D011183:Postoperative Complications / Q000401:mortality*; D015995:Prevalence; D011647:Puerto Rico / Q000453:epidemiology; D012042:Registries / Q000706:statistics & numerical data*; D018570:Risk Assessment; D012307:Risk Factors; D015607:Stents; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology; D055815:Young Adult